Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer

Table 2 Quantification of crizotinib in the plasma of patients, adjusted doses, and adverse events

Patient	Daily dose of crizotinib ^a (mg/day)	Trough concentration (ng/mL (μM))	Tumor response on day 28	Crizotinib-induced adverse events ^b
1	400^a	589.3 (1.31)	SD	Fatigue, staggering, dysgeusia, neutropenia***, AST elevation
2	500	314.1 (0.70)	SD	Nausea, neutropenia
3	500	370.8 (0.82)	SD	Fatigue, AST and ALT elevations
4	500	825.2 (1.83)	SD	Fatigue, staggering, eye disorder, dysgeusia, nausea, anorexia, AST elevation, constipation
5	500	847.8 (1.88)	SD	Fatigue, eye disorder, dysgeusia, nausea, vomiting, constipation, diarrhea, rise in creatinine levels, leukopenia*, neutropenia**, AST and ALT elevations
6	500	470.8 (1.05)	SD	Fatigue, eye disorder, dysgeusia, constipation, diarrhea, neutropenia, AST elevation
7	500	573.6 (1.27)	SD	Staggering, anorexia, dysgeusia, nausea, constipation, neutropenia, vomiting, AST elevation, QT interval prolongation***
8	500	508.5 (1.13)	SD	Nausea, vomiting, anorexia, neutropenia, AST and ALT elevations***
9	500	243.5 (0.54)	SD	Eye disorder

AST; aspartate aminotransferase, ALT; alanine aminotransferase, SD; stable disease.
^aPlasma collection was conducted after the dosage had been adjusted due to crizotinib-induced adverse events. The plasma of patients was collected at day 14 before crizotinib was taken in the morning and was analyzed as the trough sample.
^bAll adverse events developed in each patient at days 7, 14, 21 and 28 were listed.
***is grade 3, ****is grade 4, and other adverse events were grade 1 or 2.

ISSN: 2055-0294